Studieoverzicht

 
 
  2017-02 PERIDENO       Closed       Adjuvant       HER2-, any HR       Postmenopausal  
  2017-01 NEOLBC       Open       Neoadjuvant       HER2- HR+       Postmenopausal  
  2016-01 TOP-1       Open       Data registration       HER2- HR+       Postmenopausal  
  2015-02 MonaLEEsa-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2015-01 Monarch-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2014-01 MONALEESA-2       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-06 Biomarker Study Everolimus       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-05 BELLE-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2012-01 BALLET       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2011-01 Abiraterone       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2009-05 BOLERO 2       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2006-05 IDEAL       Follow up       Adjuvant       Any HER2, HR+       Postmenopausal  
  2006-04b TEAM IIb       Closed       Adjuvant       Any HER2, HR+       Postmenopausal  
  2006-04a TEAM IIa       Closed       Neoadjuvant       Any HER2, HR+       Postmenopausal  
  2006-02 OMEGA       Closed       Advanced/metastatic       Any HER2, any HR       Postmenopausal  
  2006-01 DATA       Follow up       Adjuvant       Any HER2, HR+       Postmenopausal  
  2001-01 TEAM       Closed       Adjuvant       Any HER2, HR+       Postmenopausal